Neuroblastoma, a kind of cancer that attacks the nervous system of the young children finally has been defeated. It is Keryx Biopharmaceuticals Inc which has orphan drug status for its cancer drug, perifosine. In U. S, there are 200,000 people who are affected by the perifosine. This orphan drug status means that the Keryx Biopharmaceuticals Inc can get intensive during the development of the drug and seven years exclusive marketing rights if the drug is the first drug which can give the right treatment for the sufferers of the diseases. That exclusive marketing right is also available if the new drugs can become more effective drugs than the drugs or therapies before. The holder of this orphan drug status is The Food and Drug Administration of U. S.
The Neuroblastoma itself becomes serious disease after causing 650 new cases each year. Unfortunately, the drugs or treatments for this Neuroblastoma are limited. Keryx Biopharmaceuticals Inc offers the way out from this disease by its drug, perifosine. This company says that this drug has passed many trials and it has been proved as the right drug for curing the Neuroblastoma. Keryx Biopharmaceuticals Inc has also tested it for the other kinds of cancer such as colorectal cancer or multiple myeloma, a cancer of the blood.
For the guarantee or proof of the drugs, FDA has given the orphan drug status too for this company. They has given that status in case of the perifosine usage for the colorectal cancer, not just Neuroblastoma. This drug itself has marketed in North America. In Canada, there is Drug maker Aeterna Zentaris which has in marketing or distributing this perifosine around the world except South Korea. That selling also influences the condition of the stock of Keryx. Its stocks have increased significantly together with the stocks of Aeterna Zentaris.